Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab, Chidamide, and Lenalidomide for Relapsed/Refractory AITL
NCT04319601Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Mar 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, tucidinostat, lenalidomide in angioimmunoblastic T-cell lymphoma (AITL), sponsored by Zhejiang Cancer Hospital. Status: unknown.
02
Drugs
rituximabtucidinostatlenalidomide
03
Conditions
angioimmunoblastic T-cell lymphoma (AITL)
Beyond the preview
Go deeper on NCT04319601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04319601.